Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.62 |
| ▸ | CD74 | P04233 | 1/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.53 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.53 |
| ▸ | DDT | P30046 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207017 | 0.85 | KDM4E (0.69) | KMOCD74MIFRXRARXRB | |
| SCHEMBL29800516 | 0.85 | KDM4E (0.69) | KMOCD74MIFRXRARXRB | |
| SCHEMBL16114065 | 0.85 | KMO (0.58) | KMOCD74MIFRXRARXRB | |
| SCHEMBL28069322 | 0.83 | KMO (0.67) | KMOCD74MIFRXRARXRB | |
| SCHEMBL31734205 | 0.83 | KMO (0.67) | KMOCD74MIFRXRARXRB | |
| SCHEMBL1296686 | 0.83 | KMO (0.56) | KMOCD74MIFRXRARXRB | |
| SCHEMBL30725957 | 0.83 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL29904709 | 0.83 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL71238 | 0.83 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL4631461 | 0.82 | PRKCI (0.54) | KAT6ANPC1RAB9AMAPK1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215150-B1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3307258-B1 | ARYL SULFONOHYDRAZIDES | UNIV MONASH (AU) | 2020-12-16 | — | — | EP | disclosed |
| US-10829446-B2 | Aryl sulfonohydrazides | MONASH UNIVERSITY (AU) | 2020-11-10 | — | — | US | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180222857-A1 | ARYL SULFONOHYDRAZIDES | MONASH UNIVERSITY (AU) | 2018-08-09 | — | — | US | disclosed |
| US-20180222857-A1 | ARYL SULFONOHYDRAZIDES | MONASH UNIVERSITY (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-2743256-B1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-3215150-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9682925-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-20 | — | — | US | disclosed |
| WO-2016198507-A1 | ARYL SULFONOHYDRAZIDES | MONASH UNIVERSITY (AU) | 2016-12-15 | — | — | WO | disclosed |
| US-20110009385-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112839-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| CN-1075716-A | The drying of plant materials part and the method that comes off | BASF AG (DE) | 1993-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222857-A1 | ARYL SULFONOHYDRAZIDES | FPR3, NCOA3, HAT1 | KMO 2194/4885CD74 2492/4885MIF 1716/4885 |
| US-20110009385-A1 | COMPOUNDS | CTSK, CTSS, MMP9 | KMO 2550/4885CD74 3187/4885MIF 841/4885 |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | KMO 4524/4885CD74 2149/4885MIF 107/4885 |
| US-10829446-B2 | Aryl sulfonohydrazides | FPR3, NCOA3, HAT1 | KMO 2194/4885CD74 2492/4885MIF 1716/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 495/4885CD74 830/4885MIF 1358/4885 |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | KMO 429/4885CD74 3797/4885MIF 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.